Literature DB >> 11533635

Monoclonal antibodies in the clinic.

J M Reichert1.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11533635     DOI： 10.1038/nbt0901-819

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  27 in total

1.  Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.

Authors:  Christoph Rader; Subhash C Sinha; Mikhail Popkov; Richard A Lerner; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

2.  Immunology at the crossroads. As decades of research have resulted in few clinical applications, it is time to think about new research strategies to understand the workings of the immune system.

Authors:  Antonio Coutinho
Journal:  EMBO Rep       Date:  2002-11       Impact factor: 8.807

3.  IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.

Authors:  Johan Nilvebrant; D Cameron Dunlop; Aroop Sircar; Thierry Wurch; Emilia Falkowska; Janice M Reichert; Gustavo Helguera; Emily C Piccione; Simon Brack; Sven Berger
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

Review 4.  Metrics for antibody therapeutics development.

Authors:  Janice M Reichert
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

Review 5.  Mining human antibody repertoires.

Authors:  Roger R Beerli; Christoph Rader
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

6.  Equipment characterization to mitigate risks during transfers of cell culture manufacturing processes.

Authors:  Christian Sieblist; Marco Jenzsch; Michael Pohlscheidt
Journal:  Cytotechnology       Date:  2015-08-01       Impact factor: 2.058

Review 7.  Biologic therapies: what and when?

Authors:  Sarah L Johnston
Journal:  J Clin Pathol       Date:  2007-01       Impact factor: 3.411

8.  4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland.

Authors:  Alain Beck; Sherif Hanala; Janice M Reichert
Journal:  MAbs       Date:  2009-03-20       Impact factor: 5.857

9.  Probabilities of success for antibody therapeutics.

Authors:  Janice M Reichert
Journal:  MAbs       Date:  2009-07-18       Impact factor: 5.857

10.  Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.

Authors:  A Nowakowski; C Wang; D B Powers; P Amersdorfer; T J Smith; V A Montgomery; R Sheridan; R Blake; L A Smith; J D Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.